Prostate Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Prostate cancer, characterized by its lengthy disease trajectory and diverse clinical outcomes among individual patients, predominantly affects men aged 45 to 60. Risk factors associated with this cancer encompass familial predisposition, ethnicity, age, obesity, and various environmental influences, with familial inheritance being a significant genetic risk factor. The majority of newly diagnosed prostate cancer cases initially present with localized disease, typically managed through radical prostatectomy and radiation therapy, followed by androgen deprivation therapy (ADT). However, within a decade, a variable percentage of patients progress to castration-resistant prostate cancer (CRPC). Among them, those with metastatic castration-resistant prostate cancer (MCRPC) face a particularly grim prognosis, with median survival ranging from 9 to 30 months for CRPC and reduced to 9–13 months for MCRPC. Current therapeutic strategies for MCRPC include cytotoxic chemotherapy agents, androgen receptor (AR) blocking agents, immunotherapies, and radiopharmaceuticals, with taxane chemotherapy (such as docetaxel and cabazitaxel) being the standard treatment.

·       In the USA, the incidence of prostate cancer ranges from 95 to 112 cases per 100,000 population, constituting approximately 15% of all cancer diagnoses. Notably, 85% to 90% of cases of newly developed MCRPC stem from the progression of non-metastatic castration-resistant prostate cancer (nmCRPC).

 

Thelansis’s “Prostate Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prostate Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Prostate Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Prostate Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Prostate Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Prostate Cancer, Prostate Cancer market outlook, Prostate Cancer competitive landscape, Prostate Cancer market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)